Advertisement
Advertisement
U.S. Markets open in 2 hrs 57 mins
Advertisement
Advertisement
Advertisement
Advertisement

Revolution Medicines, Inc. (RVMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.53-0.19 (-0.96%)
At close: 04:00PM EDT
19.53 0.00 (0.00%)
After hours: 04:02PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.72
Open20.19
Bid0.00 x 800
Ask0.00 x 1000
Day's Range19.35 - 20.45
52 Week Range14.08 - 34.16
Volume469,633
Avg. Volume935,323
Market Cap1.439B
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-2.38
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
  • GlobeNewswire

    Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

    KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to enter clinic, following closely behind company’s RASMULTI(ON) Inhibitor, RMC-6236 REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient

  • GlobeNewswire

    Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

    Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced two senior management promotions, as well as the addition of a new member to its leadership team. Jack Anders, who previously served as the company

  • GlobeNewswire

    Revolution Medicines to Participate in Upcoming Investor Conferences

    REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the 2022 Wells Fargo Healthcare Conference and the H.C. Wainwright 24th Annual

Advertisement
Advertisement